Second Sight Chief Executive Will McGuire said that Ryan’s knowledge of manufacturing and research and development will be critical as the company continues to develop the Orion implanted cortical stimulation device to provide artificial vision to individuals who are blind.

“Pat has the perfect background to ready Second Sight for an exciting future with Orion. His strong leadership in key areas will be invaluable, as we move the Orion clinical and development programs forward and prepare for success in a market that includes hundreds of thousands of potential patients worldwide,” added Gregg Williams, chairman of the board, in a statement.

Shares in Second Sight (EYES) closed up 6 cents, or 3.6 percent, to $1.75 on the Nasdaq.